Real-world effectiveness and healthcare utilization of nivolumab for recurrent and/or metastatic squamous cell carcinoma of head and neck (R/M SCCHNC): A real-world population-based study.
Bibliographic record
Abstract
e18040 Background: Nivolumab was the first immunotherapy to have shown efficacy in platinum-resistant recurrent and/or metastatic squamous cell carcinoma of head and neck (R/M SCCHNC) in the CheckMate-141 trial. Prior to its introduction, patients with R/M SCCHNC had limited treatment options after progression on first-line treatments. We conducted a real-world population-based retrospective observational study to examine the real-world survival outcomes and resource utilization of patients with R/M SCCHNC who were treated with nivolumab. Methods: Patients with R/M SCCHNC were included in the study if they received nivolumab between January 17 th 2018 to August 31 st 2022 in Ontario, Canada. The maximum follow-up date is August 31 st , 2023. Overall survival (OS) and time-to-treatment discontinuation was assessed using Kaplan-Meier, and the Cox proportional hazard model was used to explore the association between baseline patient characteristics and all-cause death. Cumulative incidence of having an emergency department visit and hospitalization were estimated using the cumulative incidence function, taking death as a competing event. Results: A total of 498 patients who received nivolumab for R/M SCCHNC (Mean age 62.9, 78.7% male) were included in the study. The median survival time for all-cause death was 6.0 months (95% CI: 5.0 – 7.3) and median time to nivolumab discontinuation was 2.6 months (95% CI: 2.3 – 3.0). The overall survival probability at 1 year and 2 years were 31.1% (95% CI: 27.5 – 36%) and 18.5% (95% CI: 14.7 – 22.3%), respectively. A sensitivity analysis comparing OS between older patients Age ≥ 75yo (1yr: 37%, 95% CI: 24.3 – 49.7%; 2 yrs: 19%; 95% CI: 7.8 – 30.2%) and younger patients aged < 75yo (1yr: 31%, 95% CI: 26.5 – 35.5%; 2 yrs: 18.4%, 95% CI: 14.4 – 22.5%) demonstrated no significant differences (p-value 0.73). At 1-year following starting nivolumab, the cumulative incidence of emergency department visits was 50.6% (95% CI: 46.1 – 55.0%), emergency department visits leading to hospitalization was 49.6% (95% CI: 45 – 54.0%), and direct hospitalization is 22.7% (19.0 – 26.6%). Conclusions: In this real-world study, we demonstrated that survival outcomes of nivolumab were similar to those observed in CheckMate-141 trial. Moreover, we found that at one year after starting nivolumab, more than half of the patients had a hospitalization event, suggesting notable healthcare resource utilization in this population.
Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.
How this classification was reachedexpand
Full frame machine prediction
Teacher imitationNot calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.
Distilled classifier scores by category (both heads)
| Category | Codex | Gemma |
|---|---|---|
| Metaresearch | 0.002 | 0.005 |
| Meta-epidemiology (narrow) | 0.000 | 0.000 |
| Meta-epidemiology (broad) | 0.001 | 0.002 |
| Bibliometrics | 0.001 | 0.002 |
| Science and technology studies | 0.001 | 0.000 |
| Scholarly communication | 0.001 | 0.001 |
| Open science | 0.001 | 0.001 |
| Research integrity | 0.001 | 0.001 |
| Insufficient payload (model declined to judge) | 0.001 | 0.000 |
Machine scores (provisional)
The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.
Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.
score_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from itClassification
machine, unvalidatedMachine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.
How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".